Hello, I am Meletios Dimopoulos.
I work at the National Kapodistrian University of Athens in Athens, Greece, at Alexandra Hospital, and I'm here participating at EHA 2025.
At this meeting, I will also present preliminary data on a MagnetisMM trial, which evaluated a combination of elotuzumab with lenalidomide and daratumumab, as front line therapy in symptomatic, newly diagnosed patients who are considered not to be transplant eligible.
In this particular cohort, cohort G, elotuzumab was given at the dose of 76 mg every four weeks.
We were very happy to see that in the initial 34 patients who were treated, the very good partial response or better is above 90%, with an increasing number of patients achieving complete response.
These occurred with a relatively short median follow up of seven months.
As far as tolerability of the combination is concerned, we saw the expected complications from a bispecific, cytokine release syndrome.
But this was of grade one in the overwhelming majority of the patients.
Infections were prevented with adequate prophylaxis and with preemptive administration of immunoglobulins.
This combination will move now further to a randomized study where it will be the investigation arm, and the standard arm will be a combination of daratumumab with lenalidomide and dexamethasone.
This is one of the first studies that is showing a great activity with acceptable tolerability of a bispecific based combination in older patients with myeloma who are not eligible for high dose therapy.